Nanobiotix (NBTX) Stock Price

Nanobiotix Price

NYSE·CLOSED
29.25
​
Market closed

Over the last 14 years Nanobiotix grew revenue by 24.6% annually, reaching 33.62 M USD. For Nanobiotix, the net margin of -80.8% is up versus -1,775.7% a few years ago. The consensus 12-month price target for Nanobiotix is 38.00 USD, about 29.9% above where the stock trades today. Of 12 analysts, 11 rate the stock a buy — an overall Buy consensus.

Nanobiotix stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Nanobiotix business model & stock analysis

Nanobiotix, based in Paris, France, is a clinical-stage biotechnology company focused on developing innovative treatments for cancer and unmet medical needs. Its lead product, NBTXR3, uses hafnium oxide nanoparticles to treat various cancers, including sarcoma and lung cancer. The company has a partnership with Lian Oncology for development and commercialization in Asia. Listed on the stock market in December 2020, Nanobiotix employs 97 people.

Frequently asked questions about Nanobiotix

Analysts currently set an average price target of 38.00 USD for the Nanobiotix stock (median: 38.00 USD), implying +29.9 % versus the latest price. The consensus is based on 12 analyst ratings.

12 analysts currently rate the Nanobiotix stock: 11 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Nanobiotix to generate revenue of 29.05 M USD and earnings per share of -0.64 USD.

Converted at the current exchange rate, the Nanobiotix share trades at 26.11 EUR (29.25 USD).

The expected revenue of Nanobiotix is 29.05 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Nanobiotix is -30.79 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Nanobiotix is currently -45.41. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Nanobiotix stock.

The price-to-sales ratio (P/S) of Nanobiotix is currently 48.14. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Nanobiotix stock.

The Eulerpool Quality Score for Nanobiotix is 4/10.

The ISIN of Nanobiotix is US63009J1079. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Nanobiotix is NBTX. The ticker symbol is used to trade Nanobiotix shares on the stock exchange.

Fair ValueTerminal
26.32 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue per Employee
346,556.91 USD
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Currency
USD
Initial public offering
Dec 11, 2020
ISIN
US63009J1079
Market capitalization
1.49 B USDSmall Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2026
-45.41
P/Ee 2027
-124.87
P/Ee 2028
56.69
P/Ee 2029
147.73
P/Ee 2030
27.67
P/Se
48.14
EV/EBIT
—
P/B Ratio
48.89
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-221.12 %
Last updated Oct 24, 2026, 12:16 PM

Nanobiotix Peer Group

All fundamentals and in-depth analysis of Nanobiotix

Our stock analysis for Nanobiotix stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Nanobiotix. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.